B. 3-6 mos. 

As much as I hate to admit it, Covid has thrown a wrench into the plans. He needs time to do the Covid-19 trial - lets get on with it - no time to tarry - could be the best thing that has happened to RVX shareholders. Also, potential RVX partners are all involved in developing therapies and vaccines for the beast and BOM2 will most likely require >4000 participants if not more. Beginning the BOM2 trial prematurely could result in another setback or failure. The Covid mortality risk is high in the planned diabetic group.. 

I am frustrated and PO'd - when BOM started we were given dates of 2017 and 2018 at the outside. My patience is waning.

After studying the last corporate update, 12/22, it appears that they finally understand what they have and its MOA. The activity in ZE is advancing and bodes well for RVX. The list of suitors is impressive. Something has to give soon.

Chicagoest